IGFBP3 and prostate carcinoma: McLarty et al. investigated the short-term supplementation of polyphenon E (PPE) comprising 800 mg of (−)-epigallocatechin-3-gallate (EGCG) on the protein levels of hepatocyte growth factor (HGF), VEGF, IGF-I, IGF binding protein-3 (IGFBP-3), and prostate-specific antigen (PSA) in prostate cancer patients’ sera.